Publication:
Open randomized trial of oral artemether alone and a sequential combination with mefloquine for acute uncomplicated falciparum malaria

dc.contributor.authorS. Looareesuwanen_US
dc.contributor.authorP. Wilairatanaen_US
dc.contributor.authorC. Viravanen_US
dc.contributor.authorS. Vanijanontaen_US
dc.contributor.authorP. Pitisuttithumen_US
dc.contributor.authorD. E. Kyleen_US
dc.contributor.otherMahidol Universityen_US
dc.contributor.otherWalter Reed Army Institute of Researchen_US
dc.date.accessioned2018-07-04T07:44:26Z
dc.date.available2018-07-04T07:44:26Z
dc.date.issued1997-01-01en_US
dc.description.abstractOne hundred fifty-one patients with acute uncomplicated falciparum malaria were enrolled in a randomized, open-label study of oral artemether given alone for five or seven days or a sequential treatment of oral artemether followed by mefloquine. Forty patients received oral artemether, 100 mg initially, then 50 mg every 12 hr for a total dose of 500 mg over a five-day period: Group I. Fifty-eight patients received oral artemether, 100 mg initially, then 50 mg every 12 hr for a total dose of 750 mg over a seven- day period: Group II. Fifty-three patients received oral artemether, 200 mg every 8 hr for a total dose of 600 mg, followed 8 hr later with mefloquine (1,250 mg divided into two doses given 6 hr apart: Group III. All patients were admitted to the hospital for 28 days to exclude reinfection and 131 patients remained through the 28-day follow-up. Only two, nine, and nine patients in Groups I, II, and III, respectively, left the hospital prior to study completion for reasons unrelated to their treatment. Cure rates for the three groups were 74% (28 of 38) for Group I, 98% (48 of 49) for Group II, and 98% (43 of 44) for Group III. Mean fever and parasite clearance times were not significantly different (32.8, 27.5, and 31.4 hr for fever clearance times and 40.2, 40.6, and 36.7 hr for parasite clearance times of Groups I, II, and III, respectively) nor were any adverse effects seen. In vitro drug susceptibility testing of admission and recrudescent parasite isolates was conducted for 10 patients. These data showed no decreased response to artemether or dihydroartemisinin in recrudescent isolates when compared with admission isolates. The results of this study suggest that sequential treatment for two days with oral artemether (600 mg) followed by mefloquine (1,250 mg) is effective and well-tolerated in patients with acute uncomplicated falciparum malaria and may be an alternative treatment for multidrug-resistant falciparum malaria, particularly useful for treating patients in rural areas where the period of admission to the hospital should be as short as possible. A seven-day regimen of artemether alone (750 mg) is also very effective, yet requires prolonged administration of drug after malaria symptoms disappear.en_US
dc.identifier.citationAmerican Journal of Tropical Medicine and Hygiene. Vol.56, No.6 (1997), 613-617en_US
dc.identifier.doi10.4269/ajtmh.1997.56.613en_US
dc.identifier.issn00029637en_US
dc.identifier.other2-s2.0-0030854073en_US
dc.identifier.urihttps://repository.li.mahidol.ac.th/handle/20.500.14594/17985
dc.rightsMahidol Universityen_US
dc.rights.holderSCOPUSen_US
dc.source.urihttps://www.scopus.com/inward/record.uri?partnerID=HzOxMe3b&scp=0030854073&origin=inwarden_US
dc.subjectImmunology and Microbiologyen_US
dc.subjectMedicineen_US
dc.titleOpen randomized trial of oral artemether alone and a sequential combination with mefloquine for acute uncomplicated falciparum malariaen_US
dc.typeArticleen_US
dspace.entity.typePublication
mu.datasource.scopushttps://www.scopus.com/inward/record.uri?partnerID=HzOxMe3b&scp=0030854073&origin=inwarden_US

Files

Collections